Fellowship in Pediatric Hematology/Oncology
The Pediatric Hematology/Oncology Fellowship is a joint program of the Pediatric Oncology Branch, NCI, NIH and Johns Hopkins University. Fellows receive combined clinical training during their first year at both Johns Hopkins Hospital and the NIH Clinical Center, with unparalleled exposure to clinical issues in pediatric hematology/oncology. Patients seen at both institutions are largely non-overlapping, giving trainees unique exposure to a wide range of diagnoses and management strategies. Fellows also have access to a variety of basic and translational research opportunities available at both campuses during subsequent years of the program. For more information and to apply, visit NIH Graduate Medical Education (GME): Pediatric Hematology-Oncology.
2012 First Year Fellows Top (L to R): Wen-I Chang, Diana Steppan, Lisa McReynolds, Marielle Yohel Bottom (L to R): Orly Klein, Ruchika Goel, Elad Jacoby
AeRang Kim MD, PhD.
Assistant Professor, George Washington University and an Attending Physician at the Center for Cancer and Blood Disorders at the Children’s National Medical Center
AeRang Kim received her MD from the U. of Illinois at Chicago and after residency training in Pediatrics at NYU in New York came to the Washington DC area for her fellowship in Pediatric Hematology Oncology at the JHU-NCI Fellowship program. After completing the first year of her fellowship, Aerang joined the Pharmacology and Experimental Therapeutics (PET) section and focused on a research project in developmental therapeutics. At this time she enrolled in the Johns Hopkins Bloomberg School of Public Health Graduate Training Program in Clinical Investigation to study for a PhD.
AeRang received a Children’s Tumor Foundation Clinical Trial Award for the Phase I testing of sorafenib in pediatric NF1-related plexiform neruofibromas and an NIH Bench to Bedside award for the Preclinical testing of targeted agents for clinical development in NF-1. In December 2009, Aerang defended her thesis, “Development of Sorafenib for Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas.”
AeRang felt, “My PhD studies gave me a strong foundation in biostatistics, research ethics, study design and conduct-- and basically the methodological tools necessary to conduct effective clinical research. My studies complemented my research activities in the PET section/POB every step of the way from investigating and analyzing retrospective data for background and rationale to developing and implementing a clinical protocol and subsequent analysis to the writing of manuscripts and grants.”